659 related articles for article (PubMed ID: 19232032)
1. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
[TBL] [Abstract][Full Text] [Related]
2. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Goldstein BJ; Feinglos MN; Lunceford JK; Johnson J; Williams-Herman DE;
Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
Ji L; Han P; Wang X; Liu J; Zheng S; Jou YM; O'Neill EA; Golm GT; Engel SS; Kaufman KD; Shankar RR
J Diabetes Investig; 2016 Sep; 7(5):727-36. PubMed ID: 27181998
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
Williams-Herman D; Johnson J; Teng R; Golm G; Kaufman KD; Goldstein BJ; Amatruda JM
Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
Aschner P; Katzeff HL; Guo H; Sunga S; Williams-Herman D; Kaufman KD; Goldstein BJ;
Diabetes Obes Metab; 2010 Mar; 12(3):252-61. PubMed ID: 20070351
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Scott R; Loeys T; Davies MJ; Engel SS;
Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Dobs AS; Goldstein BJ; Aschner P; Horton ES; Umpierrez GE; Duran L; Hill JS; Chen Y; Golm GT; Langdon RB; Williams-Herman DE; Kaufman KD; Amatruda JM; Ferreira JC
J Diabetes; 2013 Mar; 5(1):68-79. PubMed ID: 22742523
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Raz I; Chen Y; Wu M; Hussain S; Kaufman KD; Amatruda JM; Langdon RB; Stein PP; Alba M
Curr Med Res Opin; 2008 Feb; 24(2):537-50. PubMed ID: 18194595
[TBL] [Abstract][Full Text] [Related]
12. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Krobot KJ; Ferrante SA; Davies MJ; Seck T; Meininger GE; Williams-Herman D; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2012 Aug; 28(8):1281-7. PubMed ID: 22697277
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
16. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Hanefeld M; Herman GA; Wu M; Mickel C; Sanchez M; Stein PP;
Curr Med Res Opin; 2007 Jun; 23(6):1329-39. PubMed ID: 17559733
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
Seck T; Nauck M; Sheng D; Sunga S; Davies MJ; Stein PP; Kaufman KD; Amatruda JM;
Int J Clin Pract; 2010 Apr; 64(5):562-76. PubMed ID: 20456211
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
20. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M
J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
